Innate Pharma (IPHA) to Release Earnings on Wednesday

Innate Pharma (NASDAQ:IPHA) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 13th. Parties that wish to register for the company’s conference call can do so using this link.

Innate Pharma Stock Up 0.5 %

IPHA stock opened at $1.85 on Tuesday. Innate Pharma has a fifty-two week low of $1.57 and a fifty-two week high of $3.15. The firm’s 50-day simple moving average is $2.08 and its 200 day simple moving average is $2.26.

Wall Street Analysts Forecast Growth

IPHA has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.50 price objective on shares of Innate Pharma in a report on Friday, September 13th. Evercore ISI raised shares of Innate Pharma to a “strong-buy” rating in a research note on Monday, September 16th.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.